CJC-1295 vs GHK (Glycyl-Histidyl-Lysine)

CJC-1295 and GHK (Glycyl-Histidyl-Lysine) are both research peptides studied across multiple applications, but they operate through fundamentally different biological pathways. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates pituitary GH release, whereas GHK is a naturally occurring tripeptide that modulates gene expression and tissue repair processes. This comparison explores their mechanisms, evidence levels, and safety profiles to assist researchers in selecting the appropriate tool for specific experimental models.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.

Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.

GHK is a naturally occurring tripeptide first isolated from human plasma, where its concentration declines significantly with age. Even without copper complexation, GHK demonstrates gene-regulatory activity affecting over 4,000 genes related to tissue repair, immune function, and anti-inflammatory responses. This broad modulation suggests a role in maintaining cellular homeostasis and extracellular matrix integrity. Key claims include wound healing acceleration and broad gene expression modulation, supported by in vitro and preclinical studies. However, the clinical translation of these findings remains an active area of investigation, with ongoing research into optimal delivery methods and dosing regimens.

Both peptides are studied for anti-aging applications, though their mechanisms differ markedly. CJC-1295 is primarily researched for its effects on body composition, including lean mass preservation and fat reduction, mediated through GH/IGF-1 axis activation. GHK, in contrast, is investigated for skin health, including wound healing, collagen synthesis, and anti-inflammatory effects. These distinct research focuses highlight the importance of matching peptide selection to specific experimental endpoints.

CJC-1295: Common side effects include transient flushing or a 'head rush' within 5–10 minutes post-injection, which is considered a hallmark of a potent injection and is harmless and brief. Self-reported effects include flu-like symptoms, headaches, irritability, anxiety, nausea, and mild transient hives. Water retention and edema are dose-dependent, as elevated GH causes sodium and water retention via the kidneys. GHK (Glycyl-Histidyl-Lysine): Well-tolerated in available studies, likely due to its natural presence in human plasma. No significant adverse effects have been reported in preclinical models, though long-term safety data remain limited.